Sequential cytokine therapy for pressure ulcers: Clinical and mechanistic response

Annals of Surgery

Volumn 231, Issue 4, 2000, Pages 600-611

  Robson, Martin C ^a,b   Hill, Donald P ^a,b   Smith, Paul D ^a,b   Wang, Xue ^a,b   Meyer Siegler, Katherine ^a,b   Ko, Francis ^b   VandeBerg, Jerry S ^c   Payne, Wyatt G ^a,b   Ochs, Diane ^b   Robson, Leslie E ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Bay Pines VA Medical Center   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; MESSENGER RNA; PLACEBO; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CELL ULTRASTRUCTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DECUBITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTRON MICROSCOPY; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WOUND CLOSURE; WOUND HEALING;

DOUBLE-BLIND METHOD; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; PRESSURE ULCER; RECOMBINANT PROTEINS; TREATMENT OUTCOME; UP-REGULATION; WOUND HEALING;

EID: 0034031419     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200004000-00020     Document Type: Article

References (61)

1. Lazurus GS, Cooper DM, Knighton DR, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 1994; 130:489-493.
2. Nwomeh BC, Yager DR, Cohen IK. Physiology of the chronic wound. Clin Plast Surg 1998; 25:341-356.
3. Bennett NT, Schultz GS. Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg 1993; 165:728-737.
4. Bennett NT, Schultz GS. Growth factors and wound healing. Part II: role in normal and chronic wound healing. Am J Surg 1993; 166:74-81.
5. Mast BA, Schultz GS. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wounds Rep Regen 1996; 4:411-420.
6. Tarnuzzer RW, Macauley SP, Mast BA, et al. Epidermal growth factor in wound healing: a model for the molecular pathogenesis of chronic wounds. In: Ziegler T, Pierce G, Herndon D, eds. Growth Factors and Wound Healing. New York: Springer Verlag; 1997: 206-228.
7. Cooper DM, Yu EZ, Hennessey P, et al. Determination of endogenous cytokines in chronic wounds. Ann Surg 1994; 219:688-692.
8. Pierce GF, Tarpley JE, Tseng J, et al. Detection of increased level of PDGF-AA in actively healing human wounds treated with recombinant PDGF-BB, and absence of PDGF in chronic nonhealing wounds. J Clin Invest 1995; 96:1336-1350.
9. Robson MC. Exogenous growth factor application effect on human wound healing. Progress Dermatol 1996; 30:1-7.
10. Robson MC, Phillips LG, Thomason A, et al. Platelet derived growth factor-BB for the treatment of chronic pressure ulcers. Lancet 1992; 339:23-25.
11. Robson MC, Phillips LG, Thomason A, et al. Recombinant human platelet-derived growth factor-BB in the treatment of pressure ulcers. Ann Plast Surg 1992; 29:193-201.
12. Mustoe TA, Cutler NR, Allman RM, et al. Phase II study to evaluate recombinant PDGF-BB in the treatment of pressure ulcers. Arch Surg 1994; 129:213-219.
13. Robson MC, Phillips LG, Lawrence WT, et al. The safety and effect of topically applied recombinant basic fibroblast growth factor on healing of chronic pressure sores. Ann Surg 1992; 216:401-408.
14. Brown GL, Curtsinger L, Jurkiewicz MJ, et al. Stimulation of healing of chronic wounds by epidermal growth factor. Plast Reconstr Surg 1995; 96:251-254.
15. Kucukcelebi A, Hui PS, Sahara K, et al. The effect of interleukin 1B on the inhibition of contraction caused by bacterial contamination. Surg Forum 1992; 43:715-716.
16. Robson MC, Abdullah A, Burns BF, et al. Safety and effect of topical recombinant human interleukin-1B in the management of pressure sores. Wound Rep Regen 1994; 2:177-181.
17. VandeBerg JS, Robson MC, Mihail RS. Extension of lifespan of pressure ulcer fibroblasts with recombinant human interleukin-1B. Am J Pathol 1995; 146:1273-1282.
18. Rees RS, Robson MC, Smiell SM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: a randomized, double-blinded, placebo controlled study. Wound Rep Regen 1998;6:A478.
19. Lynch SE, Nixon JC, Calvin RB, Antonaides HN. Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci USA 1987; 84:7696-7700.
20. Davidson JM, Bradley KN, Quaglino D. Reversal of the wound healing deficit in diabetic rats by combined basic fibroblast growth factor and transforming growth factor-b1 therapy. Wound Rep Regen 1997; 5:77-88.
21. Sprugel KH, McPherson JM, Clowes AW, Ross R. Effect of growth factors in vivo. Am J Pathol 1987; 129:601-611.
22. Greenhalgh DH, Sprugel KH, Murray MJ, et al. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990; 136:1235-1246.
23. Knighton DR, Fiegel VD, Austin LL, et al. Classification and treatment of nonhealing wounds: successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986; 294:322-330.
24. Knighton DR, Ciresi KF, Fiegel VD, et al. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet 1990; 170:56-60.
25. Atri SC, Mitra J, Bisht D, Misra K. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery 1990; 108:508-512.
26. Steed D, Goslen J, Hambley R, et al. Clinical trials with purified platelet releasate. In: Barbul A, Caldwell MD, Eaglestein WH, et al, eds. Clinical and Experimental Approaches to Dermal and Epidermal Repair: Normal and Chronic Wounds. New York: Wiley Liss; 1991: 103-113.
27. Krupski WC, Reilly LM, Perez S, et al. A prospective randomized trial of autologous platelet-derived wound healing factors for the treatment of chronic wounds: a preliminary report. J Vasc Surg 1991; 14:526-536.
28. Steed DL, Goslen JB, Holloway GA, et al. Randomized, prospective, double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 1992; 15:1598-1604.
29. Holloway GA, Steed DL, DeMarco MJ, et al. A randomized, controlled, multicenter, dose response trial of activated platelet supernatant, topical CT-102 in chronic, nonhealing, diabetic wounds. Wounds 1993; 5:198-206.
30. Rayner TE, Cowin AS, Cooler RD, Belford DA. Wound strength is returned to normal levels in steroid compromised rats by treatment with milk-derived growth factors. Wound Rep Regen 1997; 5:A123.
31. Belford DA, Rogers ML, Francis GL, et al. Platelet derived growth factor, insulin-like growth factors, fibroblast growth factors, transforming growth factor beta do not account for the cell growth activity present in bovine milk. J Endocrin 1997; 154:45-55.
32. Matsuoka J, Grotendorst GR. Two peptides related to platelet derived growth factor are present in human wound fluid. Proc Natl Acad Sci USA 1989; 86:4416-4420.
33. Ratatori DS, Caffee HH, Copeland EM, Schultz GS. Growth factors are present in human wound fluid. Surg Forum 1990; 41:627-630.
34. Dvonch WM, Murphey RJ, Matsuoka J, Grotendorst GR. Changes in growth factors in human wound fluid. Surgery 1992; 112:18-23.
35. Witte MB, Barbul A. General principles of wound healing. Surg Clin North Am 1997; 77:509-526.
36. Kucukcelebi A, Carp SS, Hayward PG, et al. Granulocyte-macrophage colony stimulating factor reverses the inhibition of wound contraction caused by bacterial contamination. Wounds 1992; 4:241-247.
37. Stenberg BD, Phillips LG, Hokanson JA, et al. Effect of bFGF on the inhibition of contraction caused by bacteria. J Surg Res 1991; 50:47-50.
38. Hayward PG, Hokanson J, Heggers JP, et al. Fibroblast growth factor reverses the bacterial retardation of wound contraction. Am J Surg 1992; 163:288-293.
39. Resch CS, Kerner E, Robson MC, et al. Pressure sore volume measurement: a technique to document and record wound healing. J Am Geriatr Soc 1988; 36:444-446.
40. Robson MC. Infection in the surgical patient: an imbalance in normal equilibrium. Clin Plast Surg 1979; 6:493-503.
41. Tarnuzzer RW, Macauley SP, Farmerie WG, et al. Competitive RNA templates for detection and quantitation of growth factors, cytokines, extracellular matrix components and matrix metalloproteinases by RT-PCR. Biotechniques 1996; 20:670-674.
42. 1. Nature Med 1997; 3:1209-1215.
43. Sahara K, Kucukcelebi A, Ko F, et al. Suppression of in vitro proliferative fibroblast contraction by interferon alpha-2B. Wound Rep Regen 1993; 1:22-27.
44. VandeBerg JS, Rudolph R, Hollan C, Haywood-Reid PL. Fibroblast senescence in pressure ulcers. Wound Rep Regen 1998; 6:38-49.
45. VandeBerg JS, Rudolph R. Pressure (decubitus) ulcer: variation in histopathology. A light and electron microscopic study. Human Pathol 1995; 26:195-201.
46. Robson MC, Maggi SP, Smith PD, et al. Ease of wound closure as an endpoint of treatment efficacy. Wound Rep Regen 1999; 7:90-96.
47. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-481.
48. Hokanson JA, Hayward PG, Carney DH, et al. A mathematical model for the analysis of experimental wound healing data. Wounds 1991; 3:213-220.
49. Cooper DH, Robson MC. In the evaluation of potential wound healing agents a placebo arm is not nontreatment. Wound Rep Regen 1996; 4:A128.
50. Robson MC, Phillips LG, Heggers JP, et al. Clinical studies on growth factors in pressure sores: preliminary report. In: Barbul A, Caldwell MD, Eaglestein WH, et al, eds. Clinical and Experimental Approaches to Dermal and Epidermal Repair: Normal and Chronic Wounds. New York: Wiley Liss; 1991;95-102.
51. LeGrand EK. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing. Am J Surg 1998; 176(Suppl 2A):485-545.
52. Banda MJ, Dwyer KS, Beckmann A. Wound fluid angiogenesis factor stimulates the directed migration of capillary endothelial cells. J Cell Biochem 1985; 29:183-193.
53. Jyung RW, Wu L, Pierce GF, Mustoe TA. Granulocyte-macrophage colony-stimulating factor: differential action on incisional wound healing. Surgery 1994; 115:325-334.
54. Thomassen MJ, Ahmad M, Barna BP, et al. Induction of cytokine messenger RNA and secretion in alveolar macrophages from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy. Cancer Res 1991; 51:857-862.
55. Fiddes JC, Hebda PA, Robson MC, et al. Preclinical wound healing studies with recombinant human basic fibroblast growth factor. Ann NY Acad Sci 1991; 368:316-328.
56. Alberts GF, Hsu DK, Peiflay KA, Winkles JA. Differential regulation of acidic and basic fibroblast growth factor gene expression in fibroblast growth factor-treated rat aortic smooth muscle cells. Circ Res 1994; 75:261-267.
57. Wang D, Mayo MW, Baldwin AS Jr. Basic fibroblast growth factor transcriptional autoregulation requires EGR-1. Oncogene 1997; 14:2291-2299.
58. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattice by human fibroblasts of different proliferative scar potentiation in vitro. Proc Natl Acad Sci USA 1979; 76:1274-1278.
59. Ehrlich HP. The modulation of contraction of fibroblast populated collagen lattices by types I, II, and III collagen. Tissue Cell 1988; 20:47-50.
60. β2 activates proliferative scar fibroblasts. J Surg Res 1999; 82:319-323.
61. Smith PD, Franz M, Wachtel T, Robson MC. Initiating the inflammatory phase of wound healing prior to wounding. Presented at the 41st University Surgical Residents' Program, New Orleans, LA, Feb. 11, 1999.